참고문헌
- Zangrillo A, Landoni G, Biondi-Zoccai G, et al. A metaanalysis of complications and mortality of extracorporeal membrane oxygenation. Crit Care Resusc 2013;15:172-8.
- Tolwani AJ, Wille KM. Anticoagulation for continuous renal replacement therapy. Semin Dial 2009;22:141-5. https://doi.org/10.1111/j.1525-139X.2008.00545.x
- Han SJ, Kim HS, Kim KI, et al. Use of nafamostat mesilate as an anticoagulant during extracorporeal membrane oxygenation. J Korean Med Sci 2011;26:945-50. https://doi.org/10.3346/jkms.2011.26.7.945
- Traverso CI, Caprini JA, Arcelus JI. The normal thromboelastogram and its interpretation. Semin Thromb Hemost 1995;21 Suppl 4:7-13.
- Marasco SF, Lukas G, McDonald M, McMillan J, Ihle B. Review of ECMO (extra corporeal membrane oxygenation) support in critically ill adult patients. Heart Lung Circ 2008;17 Suppl 4:S41-7.
- Sell LL, Cullen ML, Whittlesey GC, et al. Hemorrhagic complications during extracorporeal membrane oxygenation: prevention and treatment. J Pediatr Surg 1986;21:1087-91. https://doi.org/10.1016/0022-3468(86)90015-1
- Hwang SD, Hyun YK, Moon SJ, Lee SC, Yoon SY. Nafamostat mesilate for anticoagulation in continuous renal replacement therapy. Int J Artif Organs 2013;36:208-16. https://doi.org/10.5301/ijao.5000191
- Murase M, Usui A, Tomita Y, Maeda M, Koyama T, Abe T. Nafamostat mesilate reduces blood loss during open heart surgery. Circulation 1993;88(5 Pt 2):II432-6.
- Gery I, Gershon RK, Waksman BH. Potentiation of the T-lymphocyte response to mitogens: I. the responding cell. J Exp Med 1972;136:128-42.
- Gery I, Handschumacher RE. Potentiation of the T lymphocyte response to mitogens: III. properties of the mediator( s) from adherent cells. Cell Immunol 1974;11:162-9. https://doi.org/10.1016/0008-8749(74)90016-1
- Gery I, Waksman BH. Potentiation of the T-lymphocyte response to mitogens: II. the cellular source of potentiating mediator(s). J Exp Med 1972;136:143-55. https://doi.org/10.1084/jem.136.1.143
- Bronicki RA, Hall M. Cardiopulmonary bypass-induced inflammatory response: pathophysiology and treatment. Pediatr Crit Care Med 2016;17(8 Suppl 1):S272-8. https://doi.org/10.1097/PCC.0000000000000759
-
Muto S, Imai M, Asano Y. Mechanisms of the hyperkalaemia caused by nafamostat mesilate: effects of its two metabolites on
$Na^+$ and$K^+$ transport properties in the rabbit cortical collecting duct. Br J Pharmacol 1994;111:173-8. https://doi.org/10.1111/j.1476-5381.1994.tb14040.x - Muto S, Imai M, Asano Y. Mechanisms of hyperkalemia caused by nafamostat mesilate. Gen Pharmacol 1995;26: 1627-32.
피인용 문헌
- Molecular Insights into Human Transmembrane Protease Serine-2 (TMPS2) Inhibitors against SARS-CoV2: Homology Modelling, Molecular Dynamics, and Docking Studies vol.25, pp.21, 2020, https://doi.org/10.3390/molecules25215007
- Extracorporeal Life Support in Hemorrhagic Conditions: A Systematic Review vol.67, pp.5, 2018, https://doi.org/10.1097/mat.0000000000001216
- New Trends, Advantages and Disadvantages in Anticoagulation and Coating Methods Used in Extracorporeal Life Support Devices vol.11, pp.8, 2018, https://doi.org/10.3390/membranes11080617